IRD reports positive OPGX-BEST1 Phase 1/2 results and Phase 3 plan
OPGX-BEST1 Phase 1/2 results showed meaningful visual and structural improvements in all participants, with a strong safety profile and FDA alignment on pivotal trial endpoints. Cohort 2 is over-enrolled and Phase 3 dosing is planned for 2027.
Positive Phase 1/2 results for OPGX-BEST1 showed meaningful visual and structural improvements in all participants, with a strong safety profile and FDA alignment on pivotal trial endpoints. Original document: Opus Genetics, Inc. [IR…